

**REPORT****CSF1R** mosaicism in a family with hereditary diffuse leukoencephalopathy with spheroids

Florian S. Eichler,<sup>1,2,3,\*</sup> Jiankang Li,<sup>4,5,\*</sup> Yiran Guo,<sup>6,7,8,\*</sup> Paul A. Caruso,<sup>9</sup>  
Andrew C. Bjornes,<sup>2,10</sup> Jessica Pan,<sup>1,3</sup> Jessica K. Booker,<sup>11</sup> Jacqueline M. Lane,<sup>2,10,12</sup>  
Archana Tare,<sup>2,10</sup> Irma Vlasac,<sup>2,10</sup> Hakon Hakonarson,<sup>6,7,8</sup> James F. Gusella,<sup>1,2,10,13</sup>  
Jianguo Zhang,<sup>4,5,\*</sup> Brendan J. Keating<sup>6,7,8,\*</sup> and Richa Saxena<sup>2,10,12,\*</sup>

\*These authors contributed equally to this work.

Mutations in the colony stimulating factor 1 receptor (*CSF1R*) have recently been discovered as causal for hereditary diffuse leukoencephalopathy with axonal spheroids. We identified a novel, heterozygous missense mutation in *CSF1R* [c.1990G > A p.(E664K)] by exome sequencing in five members of a family with hereditary diffuse leukoencephalopathy with axonal spheroids. Three affected siblings had characteristic white matter abnormalities and presented with progressive neurological decline. In the fourth affected sibling, early progression halted after allogeneic haematopoietic stem cell transplantation from a related donor. Blood spot DNA from this subject displayed chimerism in *CSF1R* acquired after haematopoietic stem cell transplantation. Interestingly, both parents were unaffected but the mother's blood and saliva were mosaic for the *CSF1R* mutation. Our findings suggest that expression of wild-type *CSF1R* in some cells, whether achieved by mosaicism or chimerism, may confer benefit in hereditary diffuse leukoencephalopathy with axonal spheroids and suggest that haematopoietic stem cell transplantation might have a therapeutic role for this disorder.

- 1 Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA
- 2 Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA, 02114, USA
- 3 Center for Rare Neurological Diseases, Massachusetts General Hospital, Boston, MA, 02114, USA
- 4 BGI-Shenzhen, Shenzhen 518083, China
- 5 Shenzhen Key Laboratory of Neurogenomics, BGI-Shenzhen, Shenzhen 518083, China
- 6 Center for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA
- 7 Division of Human Genetics, The Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA
- 8 Department of Paediatrics, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA
- 9 Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA
- 10 Program in Medical and Population Genetics, Broad Institute, Cambridge, 02142, MA, USA
- 11 Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA
- 12 Department of Anaesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA
- 13 Department of Genetics, Harvard Medical School, Boston, MA, 02115, USA

Correspondence to: Dr Florian Eichler,  
Department of Neurology,  
Massachusetts General Hospital,  
Harvard Medical School, 55 Fruit Street, VBK 731,  
Boston, MA 02114,  
USA  
E-mail: feichler@partners.org

**Keywords:** leukodystrophy; whole exome sequencing; dementia; neuroinflammation; neurodegeneration

**Abbreviations:** HDLS = hereditary diffuse leukoencephalopathy with axonal spheroids; HSCT = haematopoietic stem cell transplantation

## Introduction

Leukodystrophies are inherited disorders affecting the white matter of the CNS. While most disorders have predominantly glial cell or myelin sheath abnormalities, some disorders include significant axonal pathology. Hereditary diffuse leukoencephalopathy with axonal spheroids (HDLS) is a progressive autosomal dominant leukodystrophy with an onset typically occurring in the fourth or fifth decade of life. Recently, Rademakers and colleagues (2012) identified mutations in *CSF1R*, encoding colony stimulating factor 1, as the cause of HDLS.

We performed exome sequencing in a family with four siblings affected by an unknown adult-onset leukoencephalopathy and found a novel heterozygous mutation in *CSF1R*. This was particularly surprising as the parents were unaffected, suggesting an autosomal recessive disorder. One of the four siblings carried the presumed diagnosis of metachromatic leukodystrophy and had stabilized after haematopoietic stem cell transplantation 15 years earlier.

## Materials and methods

### Human subjects

Ethical approval was obtained from Massachusetts General Hospital (protocol #2007P002248). Informed consent was obtained from all subjects. Epstein-Barr virus transformed lymphoblast cell lines were established in all subjects. DNA was subsequently extracted from whole blood and/or lymphoblast cell lines and from saliva and buccal swabs from suspected family members with mosaicism or chimerism of *CSF1R*.

The brain MRI in all affected siblings was consistent with a leukodystrophy, i.e. symmetrical, confluent, hyperintense signal on T<sub>2</sub>-weighted images and prominent T<sub>1</sub> hypointensity of the affected white matter relative to grey matter structures. Brain tissue was not available.

### Case histories

#### Patient II-1

This female patient developed behavioural and memory difficulties at 35 years of age. She was described as impulsive and was noted to frequently yell and shout insults. Once, she was found disoriented outside her home. Around the same time, she developed gait difficulties, described as shuffling gait with balance problems. By 36 years of age, she was wheelchair-bound and no longer able to ambulate. She was diagnosed with presumed adult-onset metachromatic leukodystrophy and a year later received an allogeneic haematopoietic stem

cell transplantation (HSCT); her unaffected brother (Patient II-5) was the donor. She successfully engrafted and her disease stabilized within 6 months from the transplant. For the next 15 years she maintained stable language function and personality and remained non-ambulatory.

#### Patient II-2

A 56-year-old male developed confusion and word-finding difficulties. Over the next 2 years, he experienced gait difficulties and required a walker. Around the same time, he developed a seizure disorder, with seizures occurring several times per month. At the present time, expressive language has deteriorated, but he understands simple commands. He can get quite aggressive and, on occasion, punch and spit at his caregivers. He does not verbalize spontaneously and is no longer able to ambulate. Testing for arylsulphatase A enzyme abnormalities was negative. No sulphatides in urine were present.

#### Patient II-3

A 54-year-old female with a history of psychological problems began having gait difficulties. Her parents noted that she was shuffling and had difficulties walking up stairs. She also became more depressed and tearful. She had a seizure-like event and was placed on gabapentin. After being unable to walk, she was placed in a long-term care facility. Testing for arylsulphatase A enzyme abnormalities was negative. No sulphatides in urine were present.

#### Patient II-4

A 55-year-old female began having behavioural difficulties, depression, and psychotic episodes. Soon after these first symptoms she developed gait difficulties and needed full-time assistance. Due to swallowing problems, she required placement of a gastric tube. At 58 years of age, she was admitted to a nursing home following a hospital admission for status epilepticus. On assessment 2 years later, she was non-verbal and non-ambulatory. She grunted and grimaced to pain, but showed no interactions with her surroundings otherwise. She passed away at 60 years of age.

### Parents and unaffected siblings

The mother (Patient I-2) is an 83-year-old homemaker with intact cognition, speech and motor abilities. The father (Patient I-1) is an 85-year-old retired tool maker and machinist. Neurological examination on parents and unaffected siblings is normal.

### Exome sequencing and Sanger sequencing

Exome sequencing of blood DNA was performed in five family members: two affected siblings (Patients II-2 and II-3), one unaffected sibling (Patient II-6) and both parents (Patients I-1

**Table 1** Clinical characteristics and *CSF1R* mutation in family with HDLS

ID	<i>CSF1R</i> p.E664K	Sex	Onset age	Death age	Initial symptom	Clinical features during course of disease development				
						Behavioural	Dementia	Depression	Parkinsonism	Seizures
I-2	Mosaic	F	.	Alive	Healthy	None	None	None	None	None
II-1	Chimeric	F	35	Alive	Impulsivity	+	+	Not described	Not described	Not described
II-2	Heterozygous	M	56	Alive	Confusion	+++	++	+	Rigidity	+
II-3	Heterozygous	F	54	60	OCD	++	++	+++	Not described	+
II-4	Heterozygous	F	55	60	Depression	++	+	+++	+	++ (status)

OCD = obsessive compulsive disorder.

and I-2). A recessive mode of inheritance was assumed, as both parents were unaffected.

A solution hybrid method was used to enrich for DNA targeting the exome (Agilent Sure-Select Human All exon 50 Mb), and sequencing was performed on the Illumina HiSeq2000 using 90-bp paired-end reads.

Unaligned Illumina reads were processed through the Broad Institute Picard suite pipeline and mapped to the hg19 reference genome using the Burrows-Wheeler alignment (BWA) algorithm (Li and Durbin, 2009). High quality indel and single nucleotide variant calling and annotation were performed using the Broad GATK2 joint analysis pipeline using standard filtering criteria (read depth  $\geq 10\%$ , genotype quality score  $\geq 30$ ). Details of solution hybrid selection and target sequence coverage are presented in Supplementary Table 1. We prioritized novel variants by excluding single nucleotide polymorphisms (SNPs) present in whole genome sequencing data from 1092 individuals (1000 Genomes Project Consortium *et al.*, 2012) or in dbSNP (Sherry *et al.*, 2001). Any known pathogenic mutations found in dbSNP were filtered out and were included in further analysis.

Sanger sequencing of a 407-bp amplicon encompassing the mutation was performed to confirm the *CSF1R* mutation in all exome-sequenced subjects and to test for segregation of the variant with disease in the family. Polymerase chain reaction (PCR) was performed in a 25  $\mu$ l volume with 40–50 ng DNA, 1  $\mu$ l of 10 mM forward primer 5' TTCATGAGCCATCCAACC3' and reverse primer 5'AGGCACAAGGAAACTTGCTC3'. Amplification conditions were 95 °C for 5 min followed by 35 cycles at 95 °C for 30 s, 60 °C for 30 s, 72 °C for 1 min and final extension at 72 °C for 10 min. PCR amplification was followed by Sanger sequencing on an ABI 3170 sequencer. PCR amplification and Sanger sequencing was also performed using DNA extracted from saliva and lymphoblastoid cell lines for two of the subjects. Mosaicism for the *CSF1R* c.1990G=>A, p.(E664K) mutation in DNA from the mother's blood was confirmed by cloning of a 2481-bp PCR product (amplified using forward primer 5'CAAGCAG GAACATGCTCTCA 3' and reverse primer 5'TGGCTAC TTCCCATGACACA3') encompassing the mutation into vector pGL3 (Promega) in 5'-3' orientation using a naturally occurring BamHI site. Sanger sequencing of six clones was performed using the 5'TTCATGAGCCATCCAACC3' primer.


For chimerism analyses, DNA isolated from donor blood, recipient (post-transplant saliva and buccal swab), and post-transplant blood samples were PCR amplified for 15 microsatellite markers and amelogenin and analysed by fluorescent capillary electrophoresis (University of North Carolina).

## Results

Affected siblings had characteristic white matter abnormalities and presented with progressive neurologic decline. Clinical characteristics are listed in Table 1. In one affected sibling (Patient II-1), early progression halted after allogeneic HSCT from her unaffected brother (Patient II-5) 15 years ago. Representative MRI findings are shown in Fig. 1.

To identify the underlying causal gene, we targeted >45 million base pairs in 157 523 exons from 15 994 genes for exome sequencing in five family members (parents, affected siblings Patients II-2 and II-3 and unaffected sibling Patient II-6), with each targeted base covered on average 51 times per individual (Supplementary Table 1). For each participant, ~872 novel protein-altering variants were found, of which ~837 were missense mutations. To find causal mutations inherited in an autosomal recessive manner, we searched for genes with novel, deleterious mutations or known recessive pathogenic mutations from dbSNP present in both alleles in both affected siblings (either homozygous or compound-heterozygous mutations) but with only one of the two deleterious mutations in the father and the other in the mother, and at most one deleterious mutation in the unaffected sibling. No such genes or variants were found.

We did identify a novel heterozygous G to A transition within exon 15 of *CSF1R* (c.1990G > A) in both affected siblings (49% of exome sequencing reads in Patient II-2 and 40% of sequencing reads in Patient II-3) that was absent in the sequences from the unaffected sibling and the father (Supplementary Table 1). The A allele is also absent in the dbSNP database (Sherry *et al.*, 2001), in 2184 chromosomes from the 1KGP (1000 Genomes Project Consortium *et al.*, 2012), in 13 006 exome sequences from the National Heart Lung and Blood Institute's Exome Sequencing Project [Exome Variant Server, NHLBI Exome Sequencing Project (ESP), Seattle, WA (URL: <http://evs.gs.washington.edu/EVS/>) (8 June 2013)] and in the ExAC database of 60 706 unrelated individuals [Exome Aggregation Consortium (ExAC), Cambridge, MA (URL: <http://exac.broadinstitute.org>) (accessed 9 July 2015)]. The resulting non-synonymous amino acid substitution, p.(E664K), is predicted to be



**Figure 1 MRI findings in HDLS.** Affected sibling Patient II-2: 60-year-old male with progressive cognitive deterioration and motor problems. His MRI shows enlarged ventricles with diffuse patchy white matter lesions more prominent in the frontal (**A**, white arrows) than in the posterior regions (**B**, black arrows). There is no contrast enhancement present.


deleterious by prediction algorithms PolyPhen-2 (Adzhubei *et al.*, 2013), SIFT (Kumar *et al.*, 2009), MutationTaster (Schwarz *et al.*, 2010), and CADD (score of 36, ranking in the 0.025 percentile of deleterious mutations) (Kircher *et al.*, 2014) and alters a site conserved across *Euteleostomi* species (NCBI Resource Coordinators, 2013) and across other CSF1/PDGF receptor family members (Fig. 2). As this residue is predicted to lie within the tyrosine kinase domain of CSF1R (Coussens *et al.*, 1986), encoded by a gene implicated previously in HDLS, a familial neurodegenerative condition with a similar phenotype (Rademakers *et al.*, 2012), we examined this variant more closely in all family members.

Sanger sequencing at the novel *CSFR1* mutation site p.(E664K) confirmed exome variant calls in all samples, and revealed that the mutation segregated with disease in affected siblings (Fig. 3). The proportion of mutant A allele for affected siblings was estimated at ~50% from Sanger sequencing of DNA from saliva (Patients II-1 and II-4) or from blood (Patients II-2 and II-3; Fig. 3). While the father (Patient I-1) did not carry the mutant A allele, DNA from the blood and saliva of the unaffected mother (Patient I-2) displayed mosaicism, with the A allele fraction of DNA estimated at ~15–20% from Sanger sequencing of saliva or blood DNA and 20% from exome sequencing of blood DNA (Fig. 3 and Supplementary Fig. 1). Based on the Sanger sequence traces, the fraction of cells carrying the mutant A allele appeared to be greater in DNA from saliva (~20% A allele; mixture of epithelial and

haematopoietic cells) than from the blood (~15% A allele; haematopoietic cells only), providing suggestive evidence that mosaicism may differ by cell type (Fig. 3). Sequencing of six subclones from the PCR product derived from the mother's blood DNA revealed one clone with the mutant A allele and five clones with the wild-type G allele (Supplementary Fig. 1). Chimerism analysis was performed for affected sibling Patient II-1 using blood spot DNA obtained >15 years after HSCT. The per cent donor chimerism, calculated from the average of 11 informative short tandem repeat markers, was 15% (standard deviation 5%).

## Discussion

Heterozygous mutations in *CSF1R* causing HDLS were first identified by Rademakers *et al.* (2012). *CSF1R* encodes a tyrosine kinase growth factor receptor for colony stimulating factor 1, the macrophage and monocyte-specific growth factor (Ridge *et al.*, 1990). This cell-surface receptor regulates survival, proliferation, and differentiation of mononuclear phagocytic cells, including microglia of the CNS (Stanley *et al.*, 1997). In the brain, CSF1R protein is predominantly expressed in microglial cells (Ginhoux *et al.*, 2010), although low levels of CSF1R have been reported in cultured neurons (Akiyama *et al.*, 1994; Raivich *et al.*, 1998; Wang *et al.*, 1999). All disease-causing mutations to date—including that of our family—are located within the tyrosine kinase domain of CSF1R.




**Figure 2** Genomic and protein localization of novel *CSF1R* mutation. **(A)** Genomic organization of the 60 kb *CSF1R* gene with 22 exons (vertical hatches); **(B)** exon structure of the human *CSF1R* cDNA, with start codon (ATG) and stop codon (TGA) shown. Arrow shows position of c.1990G > A, p.(E664K) mutation in exon 15. **(C)** Domain structure of the *CSF1R* protein showing the immunoglobulin domains (Ig) and the protein tyrosine kinase domain (PTK), interrupted by the kinase insert at amino acid positions 670–740 (shaded). **(D)** The position of the p.E664K mutation adjacent to the kinase insert within the PTK domain. **(E)** Alignment for the parts of the PTK domain surrounding p.E664K, including human CSF1/PDGF receptor family members and multiple *CSF1R* homologues.

The phenotype of HDLS is characterized by adult-onset rapidly progressive neurodegenerative disease characterized by behavioural, cognitive and motor changes. Our patients followed this course and—with the exception of the transplanted patient—were all non-verbal or dead within 10 years of symptom onset. Brain imaging showed patchy involvement of white matter, predominantly in the frontal and parietal regions. The disorder is inherited in an autosomal dominant manner, and therefore affected individuals would typically be expected to have an affected parent. In our family, however, the mother was mosaic and unaffected, conveying the false impression of a recessive pedigree and indicating that the proportion of her cells with a mutant allele was insufficient to precipitate a dementia phenotype. Alternatively her asymptomatic state could have represented a lack of penetrance or a late onset of phenotype that so far had not manifested in the 83-year-old female. A limitation of the study is that we did not have access to post-mortem tissue to verify HDLS pathology or mosaic status in various tissues.

Mosaic forms have been reported in other autosomal dominant disorders, such as neurofibromatosis 1 and hereditary haemorrhagic telangiectasia (Ruggieri and Huson, 2001; Lee *et al.*, 2011). Some patients with mosaicism have affected children, while others appear unable to pass the mutation on to offspring, suggesting that the mutation can be limited to a part of the soma and thus absent in the germ line.

No treatment is currently known to halt or alter the course of HDLS. Most patients reported to date succumb to the disease within 10 years of symptom onset (Rademakers *et al.*, 2012). To have a patient retain a high level of communication and survive beyond 15 years after symptom onset is unusual and suggests amelioration following HSCT. An individual who has undergone a successful allogeneic bone marrow transplant is chimeric, i.e. an individual comprised of multiple cell lineages derived from distinct fertilized eggs (Biesecker and Spinner, 2013). Chimerism is thus distinct from the related phenomenon of mosaicism but either chimeric or mosaic status that lowers the overall fraction of haematopoietic cells with mutant *CSF1R* alleles can be of benefit.

Only a few neurological disorders are known to benefit from HSCT. Among these are other leukodystrophies such as adrenoleukodystrophy, metachromatic leukodystrophy, and globoid cell leukodystrophy. All of these are recessive disorders that require both alleles to be defective for disease to occur. In contrast, HDLS is a dominant disorder where one mutant allele alone can compromise *CSF1R* function, with haploinsufficiency a likely cause (Konno *et al.*, 2014). HSCT may confer benefit in recessive disorders through non-cell autonomous introduction of wild-type protein, and may similarly enhance *CSF1R* signalling after partial loss in HDLS. Only a small percentage of cells were found to be corrected in the affected sibling 15 years after HSCT (15%). However, the clinical benefit of HSCT with this



small percentage of corrected cells is consistent with per cent correction seen after cell-based correction in the leukodystrophies. In particular, cerebral childhood adrenoleukodystrophy is known to stabilize after correction of only 20% of peripheral blood cells. We were not able to obtain interim assessments of levels of chimerism after transplant to determine the stability of chimerism levels over time. It is possible that stabilization occurred spontaneously in our transplanted patient and is not related to the HSCT. In that case the correction of her peripheral blood cells was coincidental to her clinical course. Late onset phenotypes are known to show variability in course, and we can therefore not exclude this possibility but find it highly unlikely given the immediately preceding precipitous decline.

While introduction of cells with wild-type *CSF1R* by HSCT may compensate for partial loss of *CSF1R* function, the alternative of over-expression of *CSF1R* beyond normal levels in individual cells, by gene therapy for example, may carry risks. An increase in *CSF1R* copy number and point mutations leading to constitutive activation of the *CSF1R* receptor has been associated with tumour development,

including haematological malignancies and renal cell carcinomas (Ridge *et al.*, 1990; Soares *et al.*, 2009).

In summary, this first report of mosaicism in *CSF1R* in a family affected by HDLS, involving a mosaic unaffected mother who passed the pathogenic mutation through her germ line to multiple children, one of whom was chimeric and showed a milder course, suggests strongly that HSCT be explored for potential therapeutic benefit in this devastating disorder.

## Acknowledgements

We thank study participants and the Shenzhen Municipal of Government of China (CXB201108250094A) for support.

## Funding

This work was supported by an Institutional Development Award to the Center for Applied Genomics from The

Children's Hospital of Philadelphia and Massachusetts General Hospital Department of Anaesthesia, Critical Care and Pain Medicine Institutional funds. F.S.E received funding from NIH (R01 NS072446, R01FD004127, R01NS082331) and PCORI; J.M.L received funding from NIH (F32DK102323) and R.S. received funding from NIH (R21HL121728, R01DK102696, R01 HL113338).

## Supplementary material

Supplementary material is available at *Brain* online.

## References

- 1000 Genomes Project Consortium, Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, et al. An integrated map of genetic variation from 1,092 human genomes. *Nature* 2012; 491: 56–65.
- Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. *Curr Protoc Hum Genet* 2013; Chapter 7: Unit 7.20.
- Akiyama H, Nishimura T, Kondo H, Ikeda K, Hayashi Y, McGeer PL. Expression of the receptor for macrophage colony stimulating factor by brain microglia and its upregulation in brains of patients with Alzheimer's disease and amyotrophic lateral sclerosis. *Brain Res* 1994; 639: 171–4.
- Biesecker LG, Spinner NB. A genomic view of mosaicism and human disease. *Nat Rev Genet* 2013; 14: 307–20.
- Coussens L, Van Beveren C, Smith D, Chen E, Mitchell RL, Isacke CM, et al. Structural alteration of viral homologue of receptor proto-oncogene *fms* at carboxyl terminus. *Nature* 1986; 320: 277–80.
- Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. *Science* 2010; 330: 841–5.
- Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J, et al. A general framework for estimating the relative pathogenicity of human genetic variants. *Nat Genet* 2014; 46: 310–315.
- Konno T, Tada M, Tada M, Koyama A, Nozaki H, Harigaya Y, et al. Haploinsufficiency of CSF-1R and clinicopathologic characterization in patients with HDLS. *Neurology* 2014; 82: 139–48.
- Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nat Protoc* 2009; 4: 1073–81.
- Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 2009; 25: 1754–60.
- Lee NP, Matevski D, Dumitru D, Piovesan B, Rushlow D, Gallie BL. Identification of clinically relevant mosaicism in type I hereditary haemorrhagic telangiectasia. *J Med Genet* 2011; 48: 353–7.
- NCBI Resource Coordinators. Database resources of the National Center for Biotechnology Information. *Nucleic Acids Res* 2013; 41: D8–D20.
- Rademakers R, Baker M, Nicholson AM, Rutherford NJ, Finch N, Soto-Ortolaza A, et al. Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. *Nat Genet* 2012; 44: 200–5.
- Raivich G, Haas S, Werner A, Klein MA, Kloss C, Kreutzberg GW. Regulation of MCSF receptors on microglia in the normal and injured mouse central nervous system: a quantitative immunofluorescence study using confocal laser microscopy. *J Comp Neurol* 1998; 395: 342–58.
- Ridge SA, Worwood M, Oscier D, Jacobs A, Padua RA. FMS mutations in myelodysplastic, leukemic, and normal subjects. *Proc Natl Acad Sci USA* 1990; 87: 1377–80.
- Ruggieri M, Huson SM. The clinical and diagnostic implications of mosaicism in the neurofibromatoses. *Neurology* 2001; 56: 1433–43.
- Schwarz JM, Rodelsperger C, Schuelke M, Seelow D. MutationTaster evaluates disease-causing potential of sequence alterations. *Nat Methods* 2010; 7: 575–6.
- Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP: the NCBI database of genetic variation. *Nucleic Acids Res* 2001; 29: 308–11.
- Soares MJ, Pinto M, Henrique R, Vieira J, Cerveira N, Peixoto A, et al. CSF1R copy number changes, point mutations, and RNA and protein overexpression in renal cell carcinomas. *Mod Pathol* 2009; 22: 744–52.
- Stanley ER, Berg KL, Einstein DB, Lee PS, Pixley FJ, Wang Y, et al. Biology and action of colony-stimulating factor-1. *Mol Reprod Dev* 1997; 46: 4–10.
- Wang Y, Berezovska O, Fedoroff S. Expression of colony stimulating factor-1 receptor (CSF-1R) by CNS neurons in mice. *J Neurosci Res* 1999; 57: 616–32.